Monday, July 29, 2019

Exact Buys Genomic Health; Market Cap Shifts $1B

Bloomberg reported on Saturday July 27 that Exact Sciences was expected to buy Genomic Health (here).

That was followed on Monday by:

  • Press release, Exact Sciences, here.
  • Article at MedTech Dive, here.
  • Article at Endpoints, here.  Biospace here.
  • Discussion of early stock movements at Yahoo Finance, here.
  • Note, Exact later trended to a value recovery (here), but the dip is still interesting.
As shown in the stock charts above, Exact Sciences was fairly stable last week and dipped about -8% (market cap decrease about -$1B) on Monday July 29.   

Genomic Health began rising last week around July 23/24, scoring a bump of about +20% in a week (market cap increase around +$500M), and +4% on Monday July 29.

Exact shareholders will own about 90% of the new combined company.   The purchase price is only a +5% premium compared to Friday's price for GHDX, but it's about a +20% premium over GHDX's 30-day valuation.


In other recent funding news, in the liquid biopsy space, Freenome raised $160M in mid-July, and Thrive raised $110M in May.


Interestingly, on the same day, Dark Daily ran an article that FIT may be as good as colonoscopy (here) based on a March 2019 article and Op Ed in Annals of Internal Medicine.

FIT is 82274 $17 or Medicare screening code G0328 ($18; 690,000 uses in CY2017, $14M).  Exact in CY2017 had 230,000 Part B uses for $119M (81528).